JP4819285B2 - 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法 - Google Patents

狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法 Download PDF

Info

Publication number
JP4819285B2
JP4819285B2 JP2001584514A JP2001584514A JP4819285B2 JP 4819285 B2 JP4819285 B2 JP 4819285B2 JP 2001584514 A JP2001584514 A JP 2001584514A JP 2001584514 A JP2001584514 A JP 2001584514A JP 4819285 B2 JP4819285 B2 JP 4819285B2
Authority
JP
Japan
Prior art keywords
antibody
seq
rabies virus
amino acid
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001584514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528803A (ja
JP2004528803A5 (enExample
Inventor
フーパー，ダグラス，シー
ディーツショールド，バーンハード
Original Assignee
トーマス・ジェファーソン・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーマス・ジェファーソン・ユニバーシティー filed Critical トーマス・ジェファーソン・ユニバーシティー
Publication of JP2004528803A publication Critical patent/JP2004528803A/ja
Publication of JP2004528803A5 publication Critical patent/JP2004528803A5/ja
Application granted granted Critical
Publication of JP4819285B2 publication Critical patent/JP4819285B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2001584514A 2000-05-16 2001-05-04 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法 Expired - Fee Related JP4819285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16
US60/204,518 2000-05-16
PCT/US2001/014468 WO2001088132A2 (en) 2000-05-16 2001-05-04 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods

Publications (3)

Publication Number Publication Date
JP2004528803A JP2004528803A (ja) 2004-09-24
JP2004528803A5 JP2004528803A5 (enExample) 2008-06-19
JP4819285B2 true JP4819285B2 (ja) 2011-11-24

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001584514A Expired - Fee Related JP4819285B2 (ja) 2000-05-16 2001-05-04 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法

Country Status (9)

Country Link
US (1) US6890532B2 (enExample)
EP (1) EP1282703B1 (enExample)
JP (1) JP4819285B2 (enExample)
AT (1) ATE411387T1 (enExample)
CA (1) CA2419148C (enExample)
DE (1) DE60136174D1 (enExample)
IL (1) IL152825A (enExample)
RU (1) RU2272809C2 (enExample)
WO (1) WO2001088132A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
WO2002016437A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
ATE557040T1 (de) * 2001-08-21 2012-05-15 Univ Jefferson Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) * 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
SI1851315T1 (sl) * 2005-02-02 2014-06-30 University Of Massachusetts Humana protitelesa proti steklini in njihova uporaba
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU3432389A (en) 1988-04-07 1989-11-03 Farmitalia Carlo Erba S.R.L. Human monoclonal antibodies against rabies virus
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES

Also Published As

Publication number Publication date
DE60136174D1 (de) 2008-11-27
WO2001088132A2 (en) 2001-11-22
CA2419148C (en) 2011-07-12
WO2001088132A3 (en) 2002-07-18
IL152825A0 (en) 2003-06-24
JP2004528803A (ja) 2004-09-24
US6890532B2 (en) 2005-05-10
IL152825A (en) 2009-07-20
EP1282703A2 (en) 2003-02-12
CA2419148A1 (en) 2001-11-22
ATE411387T1 (de) 2008-10-15
EP1282703B1 (en) 2008-10-15
US20030165507A1 (en) 2003-09-04
RU2272809C2 (ru) 2006-03-27

Similar Documents

Publication Publication Date Title
JP4819285B2 (ja) 狂犬病ウイルス特異的ヒトモノクローナル中和抗体及び核酸及び関連する方法
CN113354729B (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
US9290786B2 (en) Monoclonal antibody production by EBV transformation of B cells
AU2004215125B2 (en) Monoclonal antibody production by EBV transformation of B cells
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
Champion et al. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure
CN115043938B (zh) SARS-CoV-2及其突变株的抗体及应用
CN113354730B (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
EP1530579B1 (en) Recombinant antibodies, and compositions and methods for making and using the same
CN116836269A (zh) 抗呼吸道合胞病毒的单克隆抗体及其应用
AU2002332600A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
WO1994015969A1 (fr) Anticorps anti-vih recombine et sa preparation
Cheung et al. A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus
CN119119256B (zh) 一种乙型脑炎病毒和寨卡病毒的单克隆抗体及其应用
WO1999022008A1 (en) Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
US7071319B2 (en) Recombinant antibodies, and compositions and methods for making and using the same
JP2001510329A (ja) ヒトモノクローナル抗体
RU2769223C1 (ru) Средство и способ терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2 на основе рекомбинантного антитела и гуманизированного моноклонального антитела
HK1071898B (en) Recombinant antibodies, and compositions and methods for making and using the same
JPH06506947A (ja) 抗ウィルスハイブリッド抗体
CN121108321A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110901

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140909

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4819285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees